Cargando…

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC

SIMPLE SUMMARY: Hepatocellular carcinoma is an aggressive cancer with high mortality. The introduction of immune-checkpoint inhibitors (ICIs) targeting the programmed-cell death 1 pathway (PD-1/L1) has led to a paradigmatic change in the systemic treatment of HCC. However, the important challenges o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Yawen, Wong, Jeffrey Sum Lung, Sugimura, Ryohichi, Lam, Ka-On, Li, Bryan, Kwok, Gerry Gin Wai, Leung, Roland, Chiu, Joanne Wing Yan, Cheung, Tan To, Yau, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072916/ https://www.ncbi.nlm.nih.gov/pubmed/33919570 http://dx.doi.org/10.3390/cancers13081949

Ejemplares similares

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
por: Wong, Jeffrey Sum-Lung, et al.
Publicado: (2021)

Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2023)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review
por: Ma, Xiaoting, et al.
Publicado: (2021)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Locked in a pro-inflammatory state
por: Wang Chau, Chiu, et al.
Publicado: (2022)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Antibiotics Associated with Lower Survival in Hepatocellular Cancer Patients Receiving Immune Checkpoint Inhibitors Independent of Tumor Status
por: Cheung, Ka Shing, et al.
Publicado: (2022)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
por: Vafaei, Somayeh, et al.
Publicado: (2022)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
por: Nardin, Charlée, et al.
Publicado: (2023)

Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report
por: Lau, Kin-Sang, et al.
Publicado: (2021)

LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment
por: Cheng, Yang, et al.
Publicado: (2022)

Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence
por: Yang, Jianming, et al.
Publicado: (2023)

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
por: Zhang, Xin, et al.
Publicado: (2022)

Response to the Article on Antibiotics and Immune Checkpoint Inhibitors by Lin et al.
por: Cheung, Ka Shing, et al.
Publicado: (2022)

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
por: Bicer, Fuat, et al.
Publicado: (2023)

Combating challenges in CAR-T cells with engineering immunology
por: Wang, Clement Yisai, et al.
Publicado: (2022)

Single-Cell Approaches to Deconvolute the Development of HSCs
por: Xiang, Yang, et al.
Publicado: (2021)

Deciphering Innate Immune Cell-Tumor Microenvironment Crosstalk at a Single-Cell Level
por: Sugimura, Ryohichi, et al.
Publicado: (2022)

Immune-epigenetic crosstalk in haematological malignancies
por: Wong, Hera, et al.
Publicado: (2023)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study
por: Tenuta, Marta, et al.
Publicado: (2021)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
por: Williams, M. R., et al.
Publicado: (1986)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors
por: Chen, Jiamin, et al.
Publicado: (2023)

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
por: Casselman, Pauline, et al.
Publicado: (2023)

A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer
por: El Helali, Aya, et al.
Publicado: (2022)

The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis
por: Choi, Horace Cheuk-Wai, et al.
Publicado: (2021)

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)
por: Alradhi, Mohammed, et al.
Publicado: (2023)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

ICIS05 CONFERENCE
por: Lau, C, et al.
Publicado: (02/1)

The Icy Realm of the Rime
por: Potter, Polyxeni
Publicado: (2011)

Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
por: Li, Ye, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9cdmv21bnjht8svimjtk1b75s1